This inventor holds 25 USPTO granted patents and 1 published patent application, primarily in Antibody Engineering. Top assignees: Hoffmann-La Roche Inc., U3 Pharma Gmbh, Prothena Biosciences Limited. Active years: 2012-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Penzberg, DE (2021)
- Munich, DE (2012 - 2023)
Company Filing History:
23 out of 5,026 
2 out of 10 
1 out of 64 
Years Active: 2012-2025
Areas of Expertise:
Title: Innovations and Contributions of Jens Niewoehner in the Field of Antibody Research
Introduction
Jens Niewoehner, based in Munich, Germany, is a prominent figure in the field of biopharmaceuticals, particularly known for his groundbreaking work in antibody research. With an impressive portfolio of 24 patents, Niewoehner has made significant contributions that advance therapeutic developments.
Latest Patents
Among his latest innovations are the "Humanized anti-Tau(PS422) antibodies and methods of use," which provide humanized antibody solutions targeting the human Tau protein. This advancement opens possibilities for therapeutic interventions in neurodegenerative diseases. Additionally, he has developed "Anti-transferrin receptor antibodies with tailored affinity," which reports on an antibody that binds specifically to both human and cynomolgus transferrin receptors, showcasing a refinement in antibody affinity and efficacy determined through surface plasmon resonance.
Career Highlights
Niewoehner has worked with leading companies in the biotech sector, including Hoffmann-La Roche Inc. and U3 Pharma GmbH. His career is marked by his relentless pursuit of innovations that not only advance scientific understanding but also commercial viability in therapeutic solutions.
Collaborations
Throughout his career, Jens Niewoehner has collaborated with esteemed colleagues, including Guy Georges and Ekkehard Moessner. These partnerships have fostered an environment of shared expertise, further enhancing the impact of his research and inventions.
Conclusion
Jens Niewoehner’s contributions to antibody research illustrate the potential of innovations in improving treatments for complex diseases. His latest patents reflect a deep commitment to scientific advancement and the hope for therapeutic breakthroughs that could benefit patients worldwide. As his career progresses, the impact of his inventions will continue to be significant in the biopharmaceutical landscape.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile